Applied BioCodeTPE:6598 +1.11%76 Days Payable is 14.69 as of Dec. 2025, which is 71% below its 10-year median of 50.18. GuruFocus rates TPE:6598 with a GF Score™ of 76/100 and a GF Value™ of NT$23.33 (Fairly Valued). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Applied BioCode ranks worse than 93.58% on this metric.
The historical rank and industry rank for Applied BioCode's Days Payable or its related term are showing as below:
TPE:6598'
s Days Payable Range Over the Past 10 Years
Min: 11.84 Med: 50.18 Max: 222.35
Current: 20.03
During the past 13 years, Applied BioCode's highest Days Payable was 222.35. The lowest was 11.84. And the median was 50.18.
TPE:6598's Days Payable is ranked worse than 93.58% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs TPE:6598: 20.03
Applied BioCode's Days Payable
increased
from Dec. 2024 (8.19) to Dec. 2025 (14.69).
It may suggest that Applied BioCodedelayed paying its suppliers.
Applied BioCode Days Payable Related Terms
Applied BioCode Days Payable Historical Data
* Premium members only.
The historical data trend for Applied BioCode's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6598 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Applied BioCode's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Days Payable distribution charts can be found below:
* The bar in red indicates where Applied BioCode's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Applied BioCode's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied BioCode (TPE:6598) has a Days Payable of 14.69 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Applied BioCode and its competitors. This is 71% below median its historical median of 50.18. Over the past decade, Applied BioCode's Days Payable has ranged from 11.84 to 222.35. According to the industry distribution chart, Applied BioCode ranks #744 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 93.6%.
Is Applied BioCode's Days Payable too high?
Applied BioCode's current Days Payable of 14.69 is 71% below median its 10-year median of 50.18. Over the past 10 years, this metric has ranged from a low of 11.84 to a high of 222.35. The Medical Devices & Instruments industry median Days Payable is 68.07. Applied BioCode's value of 14.69 is 78.4% below this industry median. Based on the distribution chart, Applied BioCode ranks #744 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Applied BioCode has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #744 out of 795 companies for Days Payable. This places Applied BioCode in the lower half of its industry. The industry median Days Payable is 68.07. Applied BioCode's value of 14.69 is 78.4% below this benchmark. Historically, Applied BioCode's own Days Payable has ranged from 11.84 to 222.35 over the past decade. While the company's 10-year median is 50.18 vs. the industry median of 68.07, Applied BioCode has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Applied BioCode's current Days Payable of 14.69 is 78.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current Days Payable is 14.69, which is 71% below median its own 10-year median of 50.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.33, compared to a current price of NT$22.75 — trading 2.5% below its estimated fair value. The current Days Payable is 14.69, which is 71% below median its 10-year median of 50.18 and 78.4% below the Medical Devices & Instruments industry median of 68.07. Applied BioCode's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Days Payable is 14.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$22.75 is trading 2.5% below its estimated GF Value™ of NT$23.33.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
Days Payable: 14.69 (71% below median its 10-year median of 50.18)
GF Value™: NT$23.33 vs. price of NT$22.75 (2.5% below fair value)
Industry Position: 78.4% below the Medical Devices & Instruments median (#744 of 795)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
76GF Score
Get the complete analysis for TPE:6598
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
